Skip to main content
Atrás
VKTX logo

Viking Therapeutics, Inc.

Calidad de datos: 100%
VKTX
NASDAQ Healthcare Biotechnology
$33.20
▲ $1.03 (3.20%)
Cap. Mercado: 3.84B
Rango del Día
$32.48 $33.76
Rango de 52 Semanas
$18.92 $43.15
Volumen
1,905,132
Promedio 50D / 200D
$32.02 / $31.99
Cierre Anterior
$32.17

Quick Summary

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (627 pares)

Métrica Acción Mediana del Sector
P/E -10.7 0.3
P/B 6.0 3.0
ROE % -47.3 3.7
Net Margin % 3.8
Rev Growth 5Y % 10.0
D/E 0.0 0.2

Precio Objetivo de Analistas

Hold
$103.00 +210.2%
Low: $99.00 High: $107.00
EPS Futuro
-$4.23
Ingresos Est.
7.17M

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2030 $2.66
$2.66 – $2.66
1.30B 5
FY2029 -$1.80
-$1.80 – -$1.80
450.85M 10
FY2028 -$4.16
-$8.20 – -$0.03
154.11M 12

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-11 -$0.89 -$1.38 -55.0%
2025-10-22 -$0.70 -$0.81 -15.7%
2025-07-23 -$0.44 -$0.58 -31.8%
2025-04-23 -$0.34 -$0.41 -20.6%
2025-02-05 -$0.28 -$0.32 -14.3%
2024-10-23 -$0.24 -$0.22 +8.3%
2024-07-24 -$0.26 -$0.20 +23.1%
2024-04-24 -$0.27 -$0.26 +3.7%

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Puntos Clave

Debt/Equity of 0.00 — conservative balance sheet
Negative free cash flow of -278.69M

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-47.34%
ROIC-46.15%
Net MarginN/A
Op. MarginN/A

Seguridad

Debt / Equity
0.00
Current Ratio9.33
Interest Coverage-7023.96

Valoración

P/E Ratio
-10.67
Forward P/EN/A
P/B Ratio6.00
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0.0 Net Income (TTM) -359.64M
ROE -47.34% ROA -50.25%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -278.69M
ROIC -46.15% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.00 Current Ratio 9.33
Interest Coverage -7023.96
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -10.67 Forward P/E N/A
P/B Ratio 6.00 P/S Ratio N/A
PEG Ratio -0.05 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 535.23 Fwd Earnings Yield N/A
FCF Yield -7.26%
Market Cap 3.84B Enterprise Value 3.67B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0.0 0.0 0.0 0.0 0.0
Net Income -359.64M -109.96M -85.90M -68.87M -54.99M
EPS (Diluted) -3.19 -1.01 -0.91 -0.88 -0.70
Gross Profit -431,000.0 0.0 0.0 0.0 0.0
Operating Income -393.34M -150.92M -100.83M -70.36M -55.68M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 715.73M 908.32M 368.49M 168.53M 210.66M
Total Liabilities 76.67M 28.04M 20.07M 23.21M 8.78M
Shareholders' Equity 639.06M 880.28M 348.42M 145.32M 201.88M
Total Debt 137,000.0 1.12M 1.26M 1.56M 29,000.0
Cash & Equivalents 165.81M 26.68M 55.52M 36.63M 26.37M
Current Assets 715.60M 907.22M 367.23M 167.04M 210.53M
Current Liabilities 76.67M 27.41M 19.14M 21.95M 8.78M